Relay Therapeutics price to sales ratio RLAY

Market value divided by revenue over the last twelve months, since 2022.

Today, Oct 23, 2026: n/m; a sliver of sales
Last meaningful: 148×; May 2026
5-year median: 74.4×
5-year range: 30.3× to 195×
Peer median: 6.8×

Relay Therapeutics' price to sales ratio is not a meaningful number today: a multiple this high rests on a sliver of sales.

It was last meaningful in May 2026, at 148×.

On the days it had one over the last 5 years, its median was 74.4×, from 30.3× in Apr 2024 to 195× in Apr 2026.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	148×	112×	195×
2025	n/m a value too high to mean anything
2024	32.4×	30.3×	54.9×
2023	52.6×	35.9×	92.1×
2022	62.4×	51.1×	117×

Against its peers

Companies in Biotechnology nearest Relay Therapeutics' size, closest first, today.

Company	Price to sales ratio
RLAYRelay Therapeutics	n/m
ADMAAdma Biologics	4.7×
VCELVericel	7.1×
KRYSKrystal Biotech	20.9×
RGENRepligen	12.7×
TECHBIO-TECHNE	9.4×
HALOHalozyme Therapeutics	8.6×
NBIXNeurocrine Biosciences	4.3×
EXELExelixis	6.6×
MGTXMeiraGTx	2.2×
INCYIncyte	4.0×
Peer median	6.8×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Relay Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.